Dutch firm Royal DSM NV’s acquisition of device component maker Kensey Nash Corp. for $360 million will broaden DSM’s existing biomedical materials offerings and position the firm as a “major materials supplier” to the device industry, the company said.
Under a definitive agreement announced May 3, DSM will launch a tender offer for Kensey Nash later this month at $38.50 per share – a 33% premium to Kensey Nash’s...